Clementia Pharmaceutical Inc., of Montreal, filed its F-1 with the SEC to raise up to $115 million in an IPO. The company is developing lead compound palovarotene, a retinoic acid receptor gamma agonist, to treat fibrodysplasia ossificans progressiva (FOP) and multiple osteochondroma (MO).